



Prior Authorization Approval Criteria
Department of Pharmacy Services

Generic Name: Pregabalin

Brand Name: Lyrica

Medication Class: anticonvulsants, miscellaneous and analgesics and antipyretics, miscellaneous

FDA Approved Uses: Management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and post herpetic neuralgia (PHN).
Adjunctive therapy for adult patients with partial onset seizures (POS).
Management of fibromyalgia.

Available Dosage Forms: 8 Capsules strengths
25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg

Usual Dose: DPN- begin with 50mg tid and may be increased to 100mg tid within 1 week.
PHN- 75mg bid or 50mg tid and may be increased to 150mg bid or 100mg tid within 1 week. If patient does not experience sufficient pain relief following 2-4 weeks of treatment with 300mg/day and are able to tolerate Lyrica, may be treated with up to 300mg bid or 200mg tid.
POS- begin treatment with 300mg/day and may be increased to 600mg/day after 2-4 weeks. Dose given in 2 or 3 divided doses.
Fibromyalgia- 300mg-450mg/day in divided doses.

Duration of Therapy: indefinite

Criteria for Use for PHN, fibromyalgia or DPN: *(bullet points below are all inclusive unless otherwise noted)*

- Must be clinically diagnosed with one of the following:
 - Post herpetic neuralgia.
 - Diabetic peripheral neuropathy.
 - Fibromyalgia.
- Must have tried and failed or intolerant to tricyclic antidepressants.
- Must have tried and failed or intolerant to gabapentin.

Criteria for Use for POS: *(bullet points below are all inclusive unless otherwise noted)*

- Clinically diagnosed partial onset seizures.
- Being used as adjunctive therapy.

Contraindications:

- Patients with known hypersensitivity to pregabalin or any of its components.

Not Approved if:



- Patient does not meet the above stated criteria.
- Patient has any contraindications to the use of pregabalin.

Special Considerations:

- A structural analog of gamma aminobutyric acid (GABA) similar to gabapentin (Neurontin).
- Lyrica is renally excreted and the dose should be adjusted for patients with reduced renal function.
- Lyrica was studied at 600mg/day, there is no evidence that this dose has additional benefit and this dose was less well tolerated.
- In view of the dose-dependent adverse effects and the higher rate of treatment discontinuation due to adverse events, dosing above 300mg/day should be reserved only for those patients who have ongoing pain and are tolerating 300mg daily.

P&T Approval: _____ Date: _____